Skip to content
AnalystLens

Royalty Pharma 8-K Report, Financial Results (Feb 11, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 11, 2025
Period End
February 11, 2025
Security
RPRX
In the record · 2020–202610-K610-Q208-K80

RPRX filed 6 annual reports (10-K), 20 quarterly reports (10-Q) and 80 current reports (8-K) between 2020 and 2026.

  1. Material agreement8-K · Jul ’21Jul ’21
  2. Impairment8-K · Dec ’22Dec ’22
  3. Material agreement8-K · May ’26May ’26

01—Abstract

Summary

Summary of the 8-K filed February 11, 2025. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) reported fourth-quarter and full-year 2024 results in a press release furnished as Exhibit 99.1 to this Form 8-K dated February 11, 2025.

Royalty Receipts grew 12% to $729 milliona in Q4 2024 and 13% to $2,771 million for full year 2024, while Portfolio Receipts were $742 million in Q4 (up 1%) and $2,801 million for the full year (down 8% from $3,049 million, largely reflecting $525 million in Biohaven-related milestone payments received in 2023). Net cash provided by operating activities was $743 million in Q4 and $2,769 million for the full year, and Portfolio Cash Flow (non-GAAP) was $2,452 million for 2024, down 9%. The company deployed $2.8 billion of capital in 2024, announced $925 million of synthetic royalty transactions, and ended the year with $929 million of cash and total debt with principal value of $7.8 billion.

For 2025, the company guided Portfolio Receipts of $2,900 million to $3,050 millionb, excluding future transactions, representing expected growth of 4% to 9%. In January 2025 the Board authorized a new share repurchase program of up to $3.0 billion, of which the company intends to repurchase $2.0 billion in 2025 subject to market conditions, replacing the unused $465 million under its prior program. The company also agreed to acquire its external manager, RP Management, LLC, in a transaction valued at approximately $1.1 billion, expected to generate cash savings of greater than $100 million in 2026 and close in the second quarter of 2025 subject to shareholder approval.

02—Key points

Key Highlights

  1. Royalty Receipts rose 13% to $2,771 million in full year 2024, driven by Evrysdi, the cystic fibrosis franchise, Trelegy, Tremfya and new royalty acquisitions.
  2. Full-year Portfolio Receipts fell 8% to $2,801 million, largely reflecting $525 million of Biohaven-related milestone payments received in 2023.
  3. Q4 2024 Adjusted EBITDA (non-GAAP) was $669 million and Portfolio Cash Flow (non-GAAP) was $678 million.
  4. 2025 Portfolio Receipts guidance of $2,900 million to $3,050 million excludes future transactions and represents expected growth of 4% to 9%.
  5. New share repurchase program of up to $3.0 billion authorized in January 2025, with $2.0 billion intended for repurchases in 2025 subject to market conditions.
  6. Agreement to internalize the external manager (RP Management, LLC) for a total transaction value of approximately $1.1 billion, with cash savings expected to exceed $100 million in 2026 and $1.6 billion cumulatively over ten years.
  7. Royalty Pharma ended 2024 with $929 million of cash and equivalents and total debt with principal value of $7.8 billion.

03—Questions

Frequently Asked Questions

  1. How did Royalty Pharma perform in the fourth quarter of 2024?

    Royalty Receipts grew 12% to $729 million, while Portfolio Receipts increased 1% to $742 million. Net cash provided by operating activities was $743 million, compared with $773 million in the fourth quarter of 2023, and Adjusted EBITDA was $669 million.

  2. Why did full-year Portfolio Receipts decline in 2024?

    The filing states that Portfolio Receipts decreased 8% from $3,049 million to $2,801 million, largely reflecting $525 million in Biohaven-related milestone payments received in 2023. Royalty Receipts actually grew 13% over the same period.

  3. What is the 2025 guidance for Royalty Pharma?

    Portfolio Receipts are expected to be between $2,900 million and $3,050 million, excluding contributions from future transactions. Payments for operating and professional costs are guided at approximately 10% of Portfolio Receipts, and interest paid at $260 million; these cost and interest figures do not yet reflect the internalization transaction.

  4. What is the internalization transaction and when is it expected to close?

    Royalty Pharma agreed in January 2025 to acquire its external manager, RP Management, LLC, for a total transaction value of approximately $1.1 billion, consisting of about 24.5 million shares vesting over five to nine years, approximately $100 million in cash, and assumption of $380 million of the Manager's debt. The closing requires shareholder approval of the share issuance and is estimated for the second quarter of 2025.

  5. What is the new share repurchase program?

    In January 2025, the Board authorized repurchases of up to $3.0 billion of Class A ordinary shares. The company intends to repurchase $2.0 billion in 2025, subject to market conditions, and the amount will depend on the discount to intrinsic value at which the shares trade. It replaces the unused $465 million of the prior $1.0 billion program announced in March 2023.

04—Continue

← View all 8-K filings